List of Excipients in Branded Drug INFUGEM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	INFUGEM	gemcitabine	62756-073	HYDROCHLORIC ACID
Sun Pharmaceutical Industries Inc	INFUGEM	gemcitabine	62756-073	SODIUM CHLORIDE
Sun Pharmaceutical Industries Inc	INFUGEM	gemcitabine	62756-073	SODIUM HYDROXIDE

INFUGEM Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

INFUGEM is a preservative-free gemcitabine hydrochloride intravenous solution marketed by Fresenius Kabi. Its formulation is deliberately simple: gemcitabine hydrochloride in sodium chloride injection, with water for injection and pH adjustment. The commercial opportunity is therefore less likely to come from new excipients and more likely to come from ready-to-use presentation, stability, handling safety, supply reliability, and differentiated oncology delivery formats.[1]

What is INFUGEM and which excipients does it contain?

INFUGEM is an injectable gemcitabine hydrochloride product for intravenous administration in oncology. The FDA prescribing information identifies a solution formulation containing gemcitabine hydrochloride, sodium chloride, and water for injection. Hydrochloric acid and sodium hydroxide may be used to adjust pH.[1]

Attribute	INFUGEM profile
Active ingredient	Gemcitabine hydrochloride
Therapeutic class	Antimetabolite; nucleoside analogue
Administration	Intravenous infusion
Dosage form	Sterile injectable solution
Preservatives	None identified in the FDA label
Primary vehicle	Sodium chloride injection
Typical concentration	10 mg/mL presentation
Manufacturer	Fresenius Kabi USA, LLC
FDA pathway	Generic injectable product
Biosimilar status	Not applicable
Primary commercial setting	Hospital oncology and infusion centers

The excipient system is conventional for a cytotoxic oncology injection. It avoids surfactants, co-solvents, antimicrobial preservatives, and complex buffering systems. That reduces formulation complexity and minimizes excipient-related regulatory and compatibility risks.

What excipient strategy does INFUGEM use?

INFUGEM uses a minimum-excipient strategy. Sodium chloride provides an isotonic aqueous vehicle, while pH adjustment supports chemical stability and product quality. The formulation does not rely on a proprietary solubilizer or delivery-enhancing excipient.

Why sodium chloride is commercially useful

Sodium chloride is widely accepted in parenteral products and is familiar to hospital pharmacies. Its advantages include:

• Established regulatory history
• Broad compatibility with intravenous administration
• Low cost and global availability
• Simple compendial testing
• Low risk of supply interruption compared with specialized excipients
• Straightforward compatibility with oncology infusion workflows

The principal limitation is that sodium chloride does not provide meaningful product differentiation. Competitors can generally reproduce the same excipient architecture unless they obtain an advantage in container closure, concentration, stability, or administration format.

Why a preservative-free design matters

Gemcitabine is administered to immunocompromised patients, often through controlled hospital compounding systems. A preservative-free formulation avoids concerns associated with repeated-dose containers and preservative exposure. The single-dose vial format also aligns with cytotoxic drug handling practices.

Preservative-free products may carry higher waste when the full vial is not used. That creates a commercial opening for smaller vial sizes, dose-banded presentations, and ready-to-administer bags.

Why the absence of complex excipients matters

A simple aqueous formulation reduces the number of potential failure points. The manufacturer does not need to demonstrate the safety and compatibility of a novel surfactant, polymer, lipid, or cosolvent. This is important for a generic injectable because the main approval burden shifts toward:

• Sterility assurance
• Particulate control
• Extractables and leachables
• Container closure integrity
• Stability
• Manufacturing reproducibility
• In-use and dilution compatibility

What formulations are protected by INFUGEM?

The public FDA label identifies a conventional gemcitabine solution rather than a proprietary drug-delivery platform.[1] The commercial protection of INFUGEM therefore appears to depend primarily on regulatory approval, manufacturing capability, supply contracts, trademarks, and product execution rather than a differentiated excipient patent.

Potentially protectable formulation features in this market include:

Formulation feature	Commercial value	Likely protection route
Ready-to-use infusion bag	High	Formulation, container, and process patents
Extended refrigerated stability	High	Stability and formulation patents
Room-temperature stability	High	Formulation and packaging patents
Reduced-volume concentrate	Medium to high	Formulation and dosing patents
Closed-system transfer presentation	High	Container and device patents
Dose-banded oncology bags	Medium	Process and service protection
Alternative buffer system	Medium	Formulation patent
Lyophilized gemcitabine	Medium	Formulation and manufacturing patents
Prefilled syringe or cartridge	Selective	Device and container patents

The core INFUGEM formulation does not appear to use a distinctive excipient platform that would create a strong standalone formulation barrier. A competing manufacturer could pursue a similar sodium chloride-based solution, subject to pharmaceutical equivalence, stability, container compatibility, and FDA approval requirements.

When does INFUGEM lose exclusivity?

Gemcitabine's compound and original branded-product exclusivity have expired. Generic gemcitabine products are therefore commercially established in the United States and other major markets.

Exclusivity category	INFUGEM assessment
New chemical entity exclusivity	Expired for gemcitabine
Original Gemzar patent protection	Expired
Biosimilar exclusivity	Not applicable
Orphan-drug exclusivity	Not a general INFUGEM protection
Product-specific formulation exclusivity	No proprietary protection identified from the public label
Generic competition	Established
Main competitive barriers	Manufacturing, quality, supply, contracting, and hospital access

Patent expiry does not eliminate commercial protection. Injectable oncology products can remain difficult to compete with because of sterile manufacturing requirements, limited supplier capacity, drug-shortage exposure, and hospital purchasing agreements.

What is the Orange Book status of INFUGEM?

INFUGEM is an FDA-approved generic gemcitabine hydrochloride injectable product. The relevant regulatory record is the FDA product label and associated generic drug listing rather than a new-drug patent estate comparable to a recently launched branded therapy.[1,2]

The commercial significance of the Orange Book position is limited:

1. Gemcitabine is an established generic molecule.
2. Generic applicants can rely on the reference product's safety and efficacy history.
3. The main competitive contest concerns product quality, availability, price, and contracting.
4. Paragraph IV litigation risk is materially lower than for a new branded oncology product with unexpired listed patents.

Which companies are challenging INFUGEM?

The main competitive threat is not a single high-profile Paragraph IV challenger. It is the existing field of generic gemcitabine suppliers, including companies that market gemcitabine hydrochloride injection in different vial sizes and concentrations.

Competitor categories include:

• Generic injectable manufacturers
• Hospital-compounding suppliers
• Contract manufacturers
• Integrated oncology distributors
• Manufacturers offering ready-to-use infusion bags
• Suppliers with regional sterile-facility capacity

Potential competitors may not challenge INFUGEM directly in court. They can enter through an abbreviated new drug application, a separate generic product, private-label distribution, or institutional supply contracts.

What Paragraph IV challenges affect INFUGEM?

No major Paragraph IV campaign is associated with the basic gemcitabine hydrochloride injection formulation in the public record used for this assessment. The underlying molecule is long genericized, and the commercial field contains multiple approved gemcitabine products.

Paragraph IV risk could arise if a company develops a newer formulation, such as:

• A premixed infusion bag with extended stability
• A low-volume high-concentration formulation
• A novel buffer system
• A closed-system oncology delivery container
• A device-integrated administration system
• A formulation that reduces preparation or handling steps

Those products could generate new patents even though gemcitabine itself is off patent.

How strong is the INFUGEM patent estate?

The patent estate appears limited for the basic marketed solution. The product's formulation is based on common injectable excipients and does not, from the public label, disclose a distinctive delivery technology.

Patent-strength factor	Assessment
Active pharmaceutical ingredient	Weak; off patent
Core formulation	Moderate-to-weak; conventional excipients
Manufacturing know-how	Moderate
Sterile filling capability	Moderate-to-strong operational barrier
Container closure	Potentially protectable but not necessarily proprietary
Supply-chain qualification	Moderate commercial barrier
Hospital contracts	Strong short-term market barrier
Alternative delivery platforms	Potentially strong if patented

The strongest defensible assets are likely to be process controls, validated sterile manufacturing, stability data, packaging configurations, and customer contracts. These assets can support market share but are less durable than a composition-of-matter patent.

What commercial opportunities exist for INFUGEM excipients?

The highest-value opportunities are not likely to involve replacing sodium chloride with a novel excipient. They involve using formulation and packaging design to reduce total treatment cost and pharmacy labor.

Ready-to-use infusion bags

A premixed gemcitabine bag could eliminate or reduce pharmacy compounding steps. The value proposition includes:

• Lower hazardous-drug handling exposure
• Lower preparation labor
• Reduced compounding errors
• Better dose standardization
• Faster chair turnover in infusion centers
• Lower use of ancillary supplies

A ready-to-use bag may command a price premium even when the active ingredient is generic. The premium must be weighed against bag stability, shipping requirements, overfill, dose variability, and unused-product waste.

Extended stability

Stability is one of the most commercially valuable formulation attributes. A product with longer refrigerated or room-temperature dating can improve inventory management and reduce wastage.

Relevant development targets include:

• Longer unopened shelf life
• Longer post-puncture stability
• Longer diluted-product stability
• Reduced sensitivity to light
• Compatibility with common infusion materials
• Improved resistance to temperature excursions

Any extension claim would require supporting stability data under ICH conditions and, for a generic product, regulatory alignment with the proposed labeling and manufacturing process.

Smaller vial sizes and dose-banding

Gemcitabine dosing is commonly based on body-surface-area calculations and treatment protocols. Smaller vial sizes could reduce waste when a patient dose falls between standard vial configurations.

Commercial options include:

• Low-volume single-dose vials
• Standardized dose-band strengths
• Institutional oncology packs
• Pharmacy-specific vial assortments
• Calendar-based treatment packs

The opportunity is strongest in high-volume infusion centers where waste and preparation labor are measurable.

Closed-system transfer compatibility

Gemcitabine is a hazardous antineoplastic drug. Packaging that works efficiently with closed-system transfer devices could support hospital adoption. The commercial value would come from workflow integration rather than from a new excipient.

Relevant design considerations include:

• Vial septum performance
• Needle-free transfer compatibility
• Low residual volume
• Clear labeling of cytotoxic status
• Robust container closure integrity
• Minimization of aerosol and surface contamination risk

What manufacturing and IP barriers affect INFUGEM competition?

Sterile injectable manufacturing is the primary operational barrier. A competitor needs qualified facilities, validated aseptic processing, reliable gemcitabine API supply, and a regulatory-quality system capable of managing cytotoxic materials.

Key barriers include:

1. Aseptic processing capacity. Injectable shortages can develop when a limited number of sites experience inspection findings or production interruptions.
2. API quality. Gemcitabine hydrochloride requires controls for identity, assay, impurities, and physical properties.
3. Cytotoxic containment. Manufacturing facilities must control operator exposure and cross-contamination.
4. Container compatibility. The formulation must remain stable in the selected vial, stopper, syringe, or infusion bag.
5. Regulatory comparability. A formulation change can affect bioequivalence, stability, extractables, and labeling requirements.
6. Hospital qualification. New oncology injectables often require pharmacy review, formulary approval, and vendor onboarding.
7. Supply continuity. Buyers may prefer a higher-priced supplier with dependable allocation.

How does INFUGEM compare with alternative gemcitabine products?

Attribute	INFUGEM	Conventional generic vial	Ready-to-use bag
Excipient complexity	Low	Low	Low to moderate
Pharmacy preparation	Required or may require dilution	Usually required	Minimal
Waste reduction	Depends on vial size	Variable	Potentially better
Handling convenience	Moderate	Moderate	High
Manufacturing complexity	Standard sterile injectable	Standard sterile injectable	Higher
Formulation patent potential	Limited	Limited	Higher
Price premium potential	Limited to moderate	Low	Moderate to high
Main buyer	Hospital and infusion center	Hospital pharmacy	Integrated infusion provider

INFUGEM's basic formulation is likely to compete on dependable supply, price, and customer service. A ready-to-use product would compete on labor savings and handling efficiency.

What licensing deals could create value?

Licensing opportunities are most credible in adjacent technologies rather than in the basic INFUGEM formulation. Potential targets include:

• A premixed oncology infusion platform
• A proprietary low-sorption infusion bag
• A closed-system transfer container
• A stability-enhancing formulation process
• A dose-banding software and pharmacy workflow platform
• A contract manufacturing arrangement for ready-to-use cytotoxic bags
• Regional licensing for hospital and government supply channels

A licensing partner would need to demonstrate a measurable advantage in stability, waste reduction, administration time, or occupational safety. A conventional excipient substitution alone is unlikely to justify a substantial royalty unless it supports a clear regulatory or commercial claim.

What generic launch scenarios exist for INFUGEM?

Price-led launch

A new entrant can compete with a lower acquisition price. This strategy is vulnerable to margin compression and requires high-volume sterile capacity.

Supply-security launch

A supplier can position the product as a second-source or shortage-mitigation product. This approach may secure hospital contracts without being the lowest-price provider.

Workflow-led launch

A ready-to-use bag, smaller vial architecture, or closed-system-compatible presentation can command a premium through labor and waste savings.

Regional launch

A manufacturer can prioritize markets with limited gemcitabine availability, local oncology infrastructure, or government procurement demand. Geographic expansion requires country-specific sterile-product registrations and packaging compliance.

Key Takeaways

• INFUGEM uses a simple gemcitabine hydrochloride, sodium chloride, and water-for-injection formulation.
• The product does not appear to rely on a novel excipient platform.
• Gemcitabine is off patent, and biosimilar competition is not relevant.
• Paragraph IV risk for the conventional formulation is limited compared with newer patented oncology products.
• The strongest commercial opportunities are ready-to-use bags, extended stability, dose-banded presentations, smaller vial sizes, and closed-system compatibility.
• Manufacturing reliability, sterile capacity, cytotoxic containment, and hospital contracting are more important barriers than excipient exclusivity.
• A differentiated formulation could support new patents, but a standard excipient substitution is unlikely to create durable market protection.
• Licensing value is highest in infusion packaging, stability technology, and pharmacy workflow integration.

FAQs

Does INFUGEM contain preservatives?

The FDA label identifies no preservative in the formulation. INFUGEM is a preservative-free injectable product supplied for intravenous use.[1]

Can INFUGEM be reformulated as a premixed infusion bag?

Yes, a premixed bag is a commercially plausible development route, but it would require validation of stability, container compatibility, sterility, labeling, and administration conditions.

Is INFUGEM interchangeable with all gemcitabine injections?

Interchangeability depends on the approved product labeling, concentration, dosage form, institutional protocols, and applicable pharmacy rules. Products with different concentrations or dilution instructions should not be treated as operationally identical without review.

Does INFUGEM have biosimilar competition?

No. Gemcitabine is a small-molecule drug, so competing versions are regulated as generic drugs rather than biosimilars.

Could a new excipient create patent protection for gemcitabine?

Potentially, but the excipient would need to produce a technically meaningful and patentable result, such as improved stability, reduced degradation, better container compatibility, or a clinically useful administration advantage.

References

1. Fresenius Kabi USA, LLC. (n.d.). INFUGEM (gemcitabine hydrochloride) injection, prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and Orange Book resources. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.